@article{Luethy2006, author = {L{\"u}thy, Anja}, title = {Zeitmanagement f{\"u}r niedergelassene An{\"a}sthesisten}, series = {An{\"a}sthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : ains 41(2006)7/8, S. 514-518}, journal = {An{\"a}sthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : ains 41(2006)7/8, S. 514-518}, year = {2006}, language = {de} } @article{BeckBittlKolleretal.1999, author = {Beck, Eberhard and Bittl, A. and Koller, S. and Merkle, E. and Katalinic, A. and J{\"a}ger, W. and Lang, N.}, title = {Erfassung der fetalen Retardierung mittels Ponderal Index und Gewichtsperzentilen Assessment of Fetal Retardation via Ponderal Index and Weight Percentiles}, series = {In: Geburtsh Frauenheilk 59(1999)2, 62-69}, journal = {In: Geburtsh Frauenheilk 59(1999)2, 62-69}, pages = {62 -- 69}, year = {1999}, abstract = {Zusammenfassung Intrauterin wachstumsretardierte Neugeborene konnten ihr genetisches Wachstumspotential aufgrund einer intrauterinen Mangelversorgung nicht realisieren und werden deshalb zu klein oder zu leicht geboren. Das Merkmal „zu leicht" wird mit Hilfe von Gewichtsperzentilen quantifiziert. Kinder mit einem Gewicht< 10. Perzentile werden als „small for gestational age" (SGA) bezeichnet. Diese Einteilung ber{\"u}cksichtigt jedoch nicht die Proportionen eines Neugeborenen, so daß vor allem asymmetrisch retardierte Neugeborene, deren Gewicht zwar die 10. Perzentile noch {\"u}berschreitet, die jedoch f{\"u}r ihre K{\"o}rpergr{\"o}ße untergewichtig sind, nicht erfaßt werden. Der Ponderal Index (PI) dagegen ber{\"u}cksichtigt sowohl Gewicht als auch L{\"a}nge des Neugeborenen. Kinder mit einem PI < 10. Perzentile werden als „low Ponderal Index" (LPI) klassifiziert. Aus p{\"a}diatrischen Studien ist bekannt, daß LPI-Kinder vermehrt durch Hypoglyk{\"a}mien, Hypothermien, Hypokalz{\"a}mien und Mekoniumaspirationen/Aspirationspneumonien gef{\"a}hrdet sind. Langzeiterhebungen zeigten eine verz{\"o}gerte k{\"o}rperliche Entwicklung und geh{\"a}uft motorische oder neurologische Verhaltensauff{\"a}lligkeiten sowie schulische Probleme. Fragestellung: Ziel der vorliegenden Arbeit war die Frage, ob Mangelgeborene, insbesondere LPI-Neugeborene, auch intrapartum einer erh{\"o}hten Gef{\"a}hrdung ausgesetzt sind. Methoden: Hierzu wurden 3687 Neugeborene retrospektiv erfaßt, die anhand von Perzentilenkurven des betrachteten Kollektivs als SGA, LPI, SGA/LPI oder Vergleichskollektiv klassifiziert wurden. Ergebnisse: Unterschiede im Geburtsmodus zwischen SGA- bzw. LPI-Mangelgeborenen und eutrophen Neugeborenen waren schwach ausgepr{\"a}gt. Demgegen{\"u}ber unterschied sich die Indikation, aufgrund deren ein geburtshilflicher Eingriff vorgenommen werden mußte deutlich. Bei 31 \% aller operativ entbundenen LPI-Neugeborenen, 47 \% der SGA-Neugeborenen und 52 \% der SGA/LPI-Kinder erfolgte die operative Entbindung aus fetaler Indikation, im Vergleich zu 16 \% des Normalkollektivs. Bez{\"u}glich des „fetal outcome", das die Merkmale neonataler S{\"a}ure-Basen-Status, Apgar-Wert, Verlegung in die Kinderklinik und perinatale Mortalit{\"a}t einbezog, verhielten sich die Gruppen SGA, LPI und SGA/LPI in gleicher Weise schlechter gegen{\"u}ber dem Vergleichskollektiv. Die Unterschiede zwischen proportionierten (SGA) und dysproportionierten (LPI) Mangelgeborenen waren weniger deutlich. Schlußfolgerungen: Es zeigte sich, daß das gegenw{\"a}rtige engmaschige, geburtshilfliche Management mit nahezu permanenter CTG-{\"U}berwachung sub partu Probleme rechtzeitig erkennen und beherrschen ließ. Die Erfassung des niedrigen Ponderal Index war zur Erkennung und Vermeidung subpartaler geburtshilflicher Risikofaktoren nicht entscheidend.}, language = {de} } @article{BeckMoldenhauerMerkleetal.1998, author = {Beck, Eberhard and Moldenhauer, A. and Merkle, E. and Kiesewetter, F. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {CA 125 production an release by ovarian cancer cell lines in vitro}, series = {In: The international journal of biological markers 13(1998), 200 - 206}, journal = {In: The international journal of biological markers 13(1998), 200 - 206}, pages = {200 -- 206}, year = {1998}, language = {en} } @article{FehmBeckValeriusetal.1998, author = {Fehm, T. and Beck, Eberhard and Valerius, T. and Gramatzki, M. and J{\"a}ger, W.}, title = {CA 125 elevations in patients with malignant lymphomas}, series = {In: Tumor Biology 19(1998), 283 - 289}, journal = {In: Tumor Biology 19(1998), 283 - 289}, pages = {283 -- 289}, year = {1998}, language = {en} } @article{BeckWagnerAnselminoetal.1997, author = {Beck, Eberhard and Wagner, Maren and Anselmino, Lisa and Xu, Feng-ji and Bast Jr., Robert C. and J{\"a}ger, Wolfram}, title = {Is OVX1 a suitable marker for endometrial cancer?}, series = {In: Gynecologic Oncology 65(1997) 2, 291-296}, journal = {In: Gynecologic Oncology 65(1997) 2, 291-296}, pages = {291 -- 296}, year = {1997}, abstract = {The single most common cause leading to the diagnosis of endometrial cancer is postmenopausal bleeding. Although most patients with early-stage disease (FIGO stage I and II) can be cured, prognosis worsens considerably with increasing stage. While serum CA 125 levels are elevated only in a significant proportion of patients with advanced disease, recently a new serum marker (OVX1) for the detection of early-stage endometrial cancer was reported. Serum OVX1 levels were measured using an OVX1 radioimmunoassay (RIA) or enzyme immunoassay (EIA) in 192 patients with endometrial cancer. CA 125 levels were measured in 112 patients using the CIS ELSA CA 125 kit. Apparently healthy females had mean serum OVX1 levels measured with the OVX1-EIA of 1.34 ± 0.74 U/ml, while patients with endometriosis had mean OVX1 serum levels of 3.15 ± 2.45 U/ml. The mean OVX1 serum level for endometrial cancer patients was 2.00 ± 1.32 U/ml. These values were 2.76 ± 1.62, 6.10 ± 4.66, and 5.37 ± 3.49, respectively, using the OVX1-RIA assay. Applying a cutoff value of 2.8 U/ml, serum OVX1-EIA levels in endometrial cancer patients were increased in 25 of 127 patients (19.7\%) with stage I disease, 5 of 17 patients with stage II (29.4\%), 5 of 22 patients (22.7\%) with stage III, and 4 of 11 patients (36.4\%) with stage IV disease. Using the OVX1-RIA and a cutoff of 7.2 U/ml, serum levels were increased in 22 of 127 (17.3\%) stage I, 6 of 17 (35.3\%) stage II, 5 of 22 (22.7\%) stage III, and 6 of 11 (54.5\%) stage IV patients. Serum CA 125 levels, determined in a total of 112 patients, were elevated above 35 U/ml in 12 of 79 patients (15.2\%) with stage I, 4 of 12 patients (33.3\%) with stage II, 8 of 13 patients (61.5\%) with stage III, and all of 8 patients (100\%) with stage IV disease. While a good correlation between serum CA 125 levels and the clinical stage of the disease was found, no correlation could be detected for OVX1 and stage.}, language = {en} } @article{JaegerSauerbreiBecketal.1995, author = {J{\"a}ger, W. and Sauerbrei, W. and Beck, Eberhard and Maassen, V. and Stumpfe, M. and Meier, W. and Kuhn, W. and J{\"a}nicke, F.}, title = {Unbound MEDLINE A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer}, series = {In: Anticancer Research 15(1995)6B, 2639-2642}, journal = {In: Anticancer Research 15(1995)6B, 2639-2642}, issn = {0250-7005}, pages = {2639 -- 2642}, year = {1995}, language = {en} } @incollection{BeckMoldenhauerKiesewetteretal.1994, author = {Beck, Eberhard and Moldenhauer, A. and Kiesewetter, F. and J{\"a}ger, W. and Woldt, L. and Lang, N.}, title = {Analysis of CA 125 production and release by ovarian cancer cells in vitro}, series = {In: Current tumor diagnosis : applications, clinical relevance, research - trends / 7th Symposium on Tumor Markers, Hamburg 1993 ; Satellite Symposium Cancer of the Lung - State and Trends in Diagnosis and Therapy. Ed. by R. Klapdor. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1994. - ISBN 3-88603-509-3}, booktitle = {In: Current tumor diagnosis : applications, clinical relevance, research - trends / 7th Symposium on Tumor Markers, Hamburg 1993 ; Satellite Symposium Cancer of the Lung - State and Trends in Diagnosis and Therapy. Ed. by R. Klapdor. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1994. - ISBN 3-88603-509-3}, pages = {187 -- 191}, year = {1994}, language = {en} } @article{BeckHofmannBernhardtetal.1994, author = {Beck, Eberhard and Hofmann, M. and Bernhardt, G. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {In vitro activity of immunoconjugates between cisplatin and an anti CA125 monoclonal antibody on ovarian cancer cell lines}, series = {In: Cell Biophysics 24/25(1994)1-3, 163-173}, journal = {In: Cell Biophysics 24/25(1994)1-3, 163-173}, issn = {0163-4992}, pages = {163 -- 173}, year = {1994}, abstract = {Cis-diammine dichloro platinum (II) (CDDP), is a highly potent antineoplastic agent that is used in the treatment of ovarian cancer. However, the clinical use of CDDP is restricted by its severe side effects. In order to reduce these side effects and to enhance its therapeutic efficacy, we developed specific immunoconjugates consisting of the murine monoclonal antibody OC125 and CDDP, using diethylene triamine pentaacetic acid (DTPA) as a linker. The coupling efficiencies of the different preparations synthesized, varied between 1.10±0.42 and 2.65±1.60 mol of CDDP per mol of antibody protein. Despite the chemical modification of the antibody molecule, specific binding activity of the OC125-CDDP conjugates toward the CA125 antigen was maintained as was demonstrated by means of immunohisto-/cytochemical staining of frozen sections of ovarian cancer tissue, amniotic epithelium, and the CA125 positive ovarian cancer cell line NIH:OVCAR 3. The antiproliferative activity of the immunoconjugates was tested against the human ovarian cancer cell lines NIH:OVCAR3 and SKOV 3, applying a kinetic crystal violet microassay. Despite the promising results obtained with the specific immuno-staining of the target cells, no significant antiproliferative activity of our immunoconjugates against the cell lines tested was observed. One possible explanation for the lack of antitumor activity could be the fact that CA125 is released in large amounts by the NIH:OVCAR 3 cells. This may have prevented an efficient immunotargeting of the cancer cells by the formation of soluble immune complexes.}, language = {en} } @article{BeckRussoGliozzoetal.1994, author = {Beck, Eberhard and Russo, Pietro and Gliozzo, Biancamaria and J{\"a}ger, Wolfram and Papa, Vincenzo and Wildt, Ludwig and Pezzino, Vincenzo and Lang, Norbert}, title = {Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer}, series = {In: Gynecologic Oncology 53(1994)2, 196-201}, journal = {In: Gynecologic Oncology 53(1994)2, 196-201}, issn = {0090-8258}, pages = {196 -- 201}, year = {1994}, abstract = {Abstract The objective of this study was to test if specific insulin and insulin-like growth factor I (IGF I) receptors are expressed in ovarian cancer tissue. Thirteen tissue specimens from primary ovarian cancers, 1 specimen from a primary peritoneal carcinoma, 10 specimens from metastatic lesions of ovarian carcinomas, and 4 specimens from recurrent ovarian cancers together with 13 normal ovaries were tested for their content of insulin and IGF-I receptors, by the application of specific insulin and IGF-I receptor radioimmunoassays. The insulin receptor (IR) and IGF-I receptor (IGF R) content in the primary tumors varied between 23.8-321.4 and 16.4-554.2 ng/0.1 mg DNA, respectively. Metastatic lesions contained between 12.3 and 226.7 ng IR/0.1 mg DNA and between 7.5 and 459.4 ng IGF R/0.1 mg DNA. In recurrent tumors the receptor concentrations were in the range of 41.5-79.8 and 48.9-160.9 ng/0.1 mg DNA for insulin and IGF-I receptors, respectively. Normal ovarian tissue contained between 12.2 and 150.1 ng IR and between 21.4 and 420.1 ng IGF R per 0.1 mg DNA, respectively. As both insulin and IGF-I receptors are present in ovarian cancer tissue, the effects of insulin and IGF-I as potential growth factors in ovarian cancer should be further investigated. Copyright © 1994 Academic Press. All rights reserved.}, language = {en} } @article{BeckRussoPapaetal.1993, author = {Beck, Eberhard and Russo, P. and Papa, V. and J{\"a}ger, W. and Pezzino, V. and Wildt, L. and Vigneri, R. and Lang, N.}, title = {Nachweis von Insulin-Rezeptoren (IR) in Ovarialkarzinomgewebe}, series = {In: Archives of Gynecology and Obstetrics December 254(1993)Iss. 1-4, 1053-1054}, journal = {In: Archives of Gynecology and Obstetrics December 254(1993)Iss. 1-4, 1053-1054}, issn = {0932-0067}, pages = {1053 -- 1054}, year = {1993}, language = {de} }